{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"bluebird bio, Inc."},"Symbol":{"label":"Symbol","value":"BLUE"},"Address":{"label":"Address","value":"60 BINNEY STREET, CAMBRIDGE, Massachusetts, 02142, United States"},"Phone":{"label":"Phone","value":"+1 339 499-9300"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates."},"CompanyUrl":{"label":"Company Url","value":"https://www.bluebirdbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andrew Obenshain","title":"President, Chief Executive Officer & Director"},{"name":"Richard Colvin","title":"Chief Medical Officer"},{"name":"Thomas J. Klima","title":"Chief Operating & Commercial Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}